Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis

MT Newswires Live06-29

Polyrizon (PLRZ) said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.

The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.

The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.

Polyrizon also said the approval is valid through June 17, 2027.

Shares of Polyrizon were up more than 1% in early Monday trading.

Price: 11.49, Change: +0.21, Percent Change: +1.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647720493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647720493","market":"nz","top_or_hot":-1,"title":"Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis","media":"MT Newswires Live","content":"<html><body><p> Polyrizon (PLRZ) said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.</p><p>The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.</p><p>The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.</p><p>Polyrizon also said the approval is valid through June 17, 2027.</p><p>Shares of Polyrizon were up more than 1% in early Monday trading.</p><p>Price: 11.49, Change: +0.21, Percent Change: +1.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolyrizon Receives Approval for Human Trial of Nasarix Nasal Spray for Allergic Rhinitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-29 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Polyrizon (PLRZ) said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.</p><p>The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.</p><p>The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.</p><p>Polyrizon also said the approval is valid through June 17, 2027.</p><p>Shares of Polyrizon were up more than 1% in early Monday trading.</p><p>Price: 11.49, Change: +0.21, Percent Change: +1.86</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647720493","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647720493","pubTimestamp":1782740788,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Polyrizon  said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.Polyrizon also said the approval is valid through June 17, 2027.Shares of Polyrizon were up more than 1% in early Monday trading.Price: 11.49, Change: +0.21, Percent Change: +1.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PLRZ":"Polyrizon Ltd."},"translate_title":"Polyrizon获得Nasarix鼻喷雾剂治疗过敏性鼻炎的人体试验批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRZ":1},"content_text":"Polyrizon (PLRZ) said Monday it received approval from the Institutional Review Board, or IRB, to conduct the first human clinical trial for its Nasarix nasal spray for seasonal allergic rhinitis.The approval confirms that the planned trial's study protocol, patient consent forms, and other materials meet IRB requirements, Polyrizon said.The trial is designed to assess the efficacy, safety, and tolerability of Nasarix compared with a saline spray in blocking airborne allergens, the company added.Polyrizon also said the approval is valid through June 17, 2027.Shares of Polyrizon were up more than 1% in early Monday trading.Price: 11.49, Change: +0.21, Percent Change: +1.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647720493","isCrawlerRequest":true}